# Safety and Efficacy of CD19 CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases

> **NCT06983964** · NA · RECRUITING · sponsor: **Beijing Boren Hospital** · enrollment: 12 (estimated)

## Conditions studied

- Autoimmune Disease

## Interventions

- **GENETIC:** CD19 CART

## Key facts

- **NCT ID:** NCT06983964
- **Lead sponsor:** Beijing Boren Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-20
- **Primary completion:** 2027-02-20
- **Final completion:** 2027-09-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06983964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06983964, "Safety and Efficacy of CD19 CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT06983964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*